TOMM20 as a Potential Prognostic Biomarker in Chordoma: Results From a High-Volume, Single-Center Study.
Ida MicailySherry LeeAtrayee Basu MallickTingting ZhanRaymond O'NeillStacey GarganoBryan HozackSameep ThapaUbaldo Martinez-OutschoornJohn AbrahamWei JiangPublished in: American journal of clinical pathology (2023)
Identifying novel signaling pathways that promote chordoma growth and recurrence is critical for developing targeted therapy for chordoma. TOMM20 may be a biomarker associated with chordoma disease progression.